Tehran University of Medical Sciences Acta Biochimica Iranica 0001-5261 1 2 2023 11 11 78 82 Solaleh Emamgholipour Department of Clinical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran Zhila Maghbooli Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran Mohammad Talebpour Department of Surgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran Sattar Gorgani-Firuzjaee Department of Medical Laboratory Sciences, Faculty of Paramedicine, AJA University of Medical Sciences, Tehran, Iran Arash Shirvani Department of Medicine, Section of Endocrinology, Nutrition, Diabetes and Weight Management, Boston University Medical Center, Boston, Massachusetts, United States of America 2023 11 11 Objectives: The aim of this study is to compare three distinct bone markers in metabolically healthy and unhealthy obese and non-obese subjects, according to various metabolic health criteria. Methods: The study enrolled a total of 35 subjects, including 11 healthy normal-weight and 23 obese subjects. Based on HOMA-Beta, all participants were divided into three groups: normal weight (HOM-Beta<100%, n=11), obese (HOMA-Beta <100%, n=12), and obese (HOMA-Beta>100%, n=12). The serum levels of osteocalcin, procollagen I amino-terminal propeptide (P1NP), and beta-cross Laps as bone turnover markers, as well as serum levels of 25 (OH) vitamin D3, and PTH were analyzed. Results: Significant differences were observed in BMI, age, 25(OH)D3, FBS, Insulin, HOMAIR, and HOMA-Beta among the groups. Analysis of bone markers revealed that the serum levels of Beta-cross Laps, P1NP, and osteocalcin were significantly different among all studied groups categorized by the HOMA-Beta model. In this context, circulating levels of osteocalcin and Betacross Laps in the normal weight group (HOMA-Beta<100%) were significantly higher than the obese group (HOMA-Beta <100%). In obese patients with HOMA-Beta <100%, Beta-cross Laps and P1NP levels were lower compared to the obese group with HOMA-Beta >100%. Conclusion: The data suggests that HOMA-Beta, as an index of β-cell function, can be used in part of metabolically healthy obese (MHO) criteria and bone remodeling is altered in the context of metabolically healthy obesity. https://abi.tums.ac.ir/index.php/abi/article/view/31 https://abi.tums.ac.ir/index.php/abi/article/download/31/19